{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:08:27Z","timestamp":1790806107590,"version":"4.1.0"},"reference-count":31,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:00:00Z","timestamp":1693440000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Biomedical Chromatography"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The current research work reports the development and validation of a sensitive, robust and reproducible bioanalytical method for quantifying neratinib maleate in rat plasma. More than 85% of the drug was extracted from the plasma samples by protein precipitation. The method was optimized using Box\u2013Behnken design, a response surface method. The effect of three critical factors, viz., the pH of the buffer (<jats:italic>X<\/jats:italic><jats:sub>1<\/jats:sub>), the aqueous phase proportion in the mobile phase (<jats:italic>X<\/jats:italic><jats:sub>2<\/jats:sub>) and the mobile phase flow rate (<jats:italic>X<\/jats:italic><jats:sub>3<\/jats:sub>), was studied on two response variables, retention time (<jats:italic>Y<\/jats:italic><jats:sub>1<\/jats:sub>) and United States Pharmacopoeia (USP)\u00a0width (<jats:italic>Y<\/jats:italic><jats:sub>2<\/jats:sub>). With the highest overall desirability function value of 0.943, the obtained optimized method conditions were: <jats:italic>X<\/jats:italic><jats:sub>1<\/jats:sub>\u00a0=\u20092.4\u2009\u00b1\u20090.1; <jats:italic>X<\/jats:italic><jats:sub>2<\/jats:sub>\u00a0=\u200966.7\u2009ml, and <jats:italic>X<\/jats:italic><jats:sub>3<\/jats:sub>\u00a0=\u20090.85\u2009ml\/min. Under the optimized conditions, the values of <jats:italic>Y<\/jats:italic><jats:sub>1<\/jats:sub> and <jats:italic>Y<\/jats:italic><jats:sub>2<\/jats:sub> for a sample containing 1\u2009ppm of the drug were found to be 14.1\u2009min and 0.50\u2009\u00b1\u20090.003, respectively. Single\u2010dose intravenous bolus (7.5\u2009mg\/kg) and oral (15\u2009mg\/kg) pharmacokinetic studies were performed to determine the absolute bioavailability of the drug. The optimized bioanalytical method was sensitive enough to capture 95% of the drug eliminated from the body. The absolute oral bioavailability of the drug was 49.30%.<\/jats:p>","DOI":"10.1002\/bmc.5731","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T18:29:04Z","timestamp":1693506544000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Optimization of a HPLC\u2013UV bioanalytical method using Box\u2013Behnken design to determine the oral pharmacokinetics of neratinib maleate in Wistar rats"],"prefix":"10.1002","volume":"37","author":[{"given":"Radhika","family":"Mahajan","sequence":"first","affiliation":[{"name":"Department of Pharmacy Birla Institute of Technology and Science Pilani, Hyderabad Campus  Medchal District Telangana India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3728-353X","authenticated-orcid":false,"given":"Punna Rao","family":"Ravi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Birla Institute of Technology and Science Pilani, Hyderabad Campus  Medchal District Telangana India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Shareef","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Birla Institute of Technology and Science Pilani, Hyderabad Campus  Medchal District Telangana India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,8,31]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/S007690050440"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/pr10061082"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/chromsci\/bmab089"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.21859\/IJB.1339"},{"key":"e_1_2_7_6_1","unstructured":"CHMP. (2018).Committee for Medicinal Products for Human Use (CHMP) assessment report.https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/nerlynx-epar-public-assessment-report_en.pdf"},{"key":"e_1_2_7_7_1","unstructured":"Committee for Medicinal Products for Human Use. (2022).ICH guideline M10 on bioanalytical method validation and study sample analysis Step5.https:\/\/database.ich.org\/sites\/default\/files\/M10_Guideline_Step4_2022_0524.pdf"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.2307\/2685731"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1875-5364(16)30083-8"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2018.10.014"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2013.09.024"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41120-021-00037-y"},{"key":"e_1_2_7_13_1","unstructured":"FDA &CDER. (2018).Bioanalytical method validation guidance for industry biopharmaceutics bioanalytical method validation guidance for industry biopharmaceutics contains nonbinding recommendations.https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bioanalytical-method-validation-guidance-industry"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2017.01.014"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.3109\/03639049509026647"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hys012"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2016.03.052"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.5264"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2016.11.035"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10337-010-1869-2"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.3109\/03639045.2011.602409"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2017.01.039"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2016.09.028"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.microc.2023.108848"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s43094-022-00405-9"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1556\/AChrom.27.2015.4.2"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.3109\/03639045.2013.850710"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.5416"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aca.2019.05.063"},{"key":"e_1_2_7_30_1","unstructured":"Step. (2017).Committee for Human Medicinal Products ICH guideline Q8 (R2) on pharmaceutical development.www.ema.europa.eu\/contact"},{"key":"e_1_2_7_31_1","unstructured":"US FDA. (2017).NERLYNX. Retrieved June 1 2022 fromhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/208051s009lbl.pdf"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.17159\/0379-4350\/2015\/v68a14"}],"container-title":["Biomedical Chromatography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bmc.5731","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T21:00:45Z","timestamp":1760043645000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/bmc.5731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,31]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1002\/bmc.5731"],"URL":"https:\/\/doi.org\/10.1002\/bmc.5731","archive":["Portico"],"relation":{},"ISSN":["0269-3879","1099-0801"],"issn-type":[{"value":"0269-3879","type":"print"},{"value":"1099-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,31]]},"assertion":[{"value":"2023-05-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e5731"}}